Navigation Links
PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics
Date:3/26/2013

MANSFIELD, Mass., March 26, 2013 /PRNewswire/ -- PrimeraDx, Inc., a molecular diagnostics company, today announced it has formed a non-exclusive diagnostics co-development agreement with Quest Diagnostics (NYSE: DGX), the world's leading diagnostics information services company.  The intent of the collaboration is to co-develop and commercialize molecular diagnostic products and services with a focus on supporting clinical development of targeted therapeutics for drug developers.

Under the agreement, Quest Diagnostics has rights to use the PrimeraDx ICEPlex Platform to independently develop and use laboratory tests in early-phase biomarker and drug development studies and clinical trials with biotechnology, pharmaceutical and medical device clients of Quest Diagnostics Clinical Trials, a business of Quest Diagnostics. 

PrimeraDx will also have rights to develop and market in vitro diagnostic products, assuming FDA approvals for those targeted therapies.  In addition, Quest Diagnostics has rights to validate and offer clinical diagnostic information services, based in part on the assays created during drug development, as aids in making treatment decisions for those drugs that are successfully commercialized and FDA approved for clinical use.  

PrimeraDx launched the ICEPlex system in August 2011.  The system can simultaneously detect and quantify disparate target types, such as mRNA, miRNA, SNPs, DNA mutations, fusions and DNA methylation. Its ability to characterize complex molecular changes makes it well suited to research and development for diseases, such as cancer, that involve systemic or multiple molecular changes.  

The companies expect to direct their initial collaborations on cancer, although they may also explore opportunities in infectious diseases, genetics and other conditions.

"This collaboration with Quest Diagnostics will enable pharmaceutical and other companies to access the unique capabilities of the PrimeraDx technology in the form of targeted diagnostic services and products," said Matt McManus , MD, PhD., President and CEO of PrimeraDx.  "Quest Diagnostics' remarkable strength in clinical diagnostics makes them a superb partner to maximize the value of the ICEPlex system for biomarker, drug and diagnostic development. We look forward to working with them and their clinical trials clients to hasten the discovery and development of drugs and companion diagnostics that can improve outcomes for patients with cancer and other diseases."

About PrimeraDx
PrimeraDx is a molecular diagnostics company marketing a novel, game-changing clinical platform which combines PCR with capillary electrophoresis for multiplexed, multi-modal, molecular diagnostics used in Oncology, Infectious Disease, and Genetic testing. The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed, multi-modal, and quantitative answers to the clinic. The company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to independently develop high-value molecular diagnostic products. Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes. PrimeraDx's technology represents the next generation of quantitative, multiplex PCR. The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysian Technology Development Corporation. The Company's website is: www.primeradx.com.

CONTACT:  Ted Myles, CFO, (508) 618-2300


'/>"/>
SOURCE PrimeraDx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The Trendlines Group Announces Co-development Agreement with Endo
2. Dr. David L. Blecker MD, MPH, F.A.C.P. Joins Inergetics Advisory Board to Co-Develop and Market Products to Penetrate Nephrology Market
3. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
4. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
5. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
6. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
7. DMG is Proud to Announce that CD Diagnostics will be Featured in an Upcoming Episode of Health Heroes
8. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
9. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
10. QualityStar Presenting at Biomarkers & Diagnostics World Congress
11. Ariosa Diagnostics Welcomes New Board Member Michael A. Aicher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The University of Connecticut, ... funding to three startups through the UConn Innovation Fund. The $1.5 million UConn ... affiliated with UConn. , The UConn Innovation Fund provides investments of up to ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant from ... , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, ...
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences , the ... and healthcare industries, is pleased to announce Holger Braemer as Vice President ... Europe GmbH” based in Germany. , Braemer is an integral part of USDM’s ...
(Date:4/20/2017)... ... April 20, 2017 , ... Energetiq ... applications, announced today that Chief Executive Officer (CEO) Debbie Gustafson has been appointed ... the global industry association connecting the electronics manufacturing supply chain. The mission of ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):